Pharmaceuticals
46 companies listed on NSE in this sector
Total revenue grew 135.59% YoY in H1 FY26 to INR 43.74 Cr, driven by volume expansion in CDMO and private label formulations across oral solids, liquids, and powders. FY25 revenue ...
Revenue from operations (Pharma Trading) fell 50.34% YoY from INR 613.69 Lakhs to INR 304.75 Lakhs.
The Pharmaceutical Intermediates segment grew 50% YoY to INR 854 Cr in FY25, while the Specialty Chemicals segment grew 2.2% YoY to INR 152.9 Cr. Total revenue for Q2 FY26 reached ...
Total revenue grew 8.5% YoY to INR 281 Cr in FY24 from INR 259 Cr in FY23. Growth is primarily driven by the fluid therapy segment (LVP and SVP) and the high-margin Steriport segme...
Consolidated revenue from operations grew by 13.03% YoY, reaching INR 19,618.53 Lakhs in FY25 compared to INR 17,357.05 Lakhs in FY24. Segment-specific growth percentages for Pharm...
API segment contributed 70% of H1 FY26 revenue, while Intermediates contributed 27.2%. Total income for Q2 FY26 grew 116% YoY to INR 52.23 Cr from INR 24.21 Cr. H1 FY26 total incom...
Not disclosed in available documents.
Not disclosed in available documents.
No documents found
Total revenue for FY25 was approximately INR 66.50 Cr, representing a 22.5% decline from INR 85.83 Cr in FY24. Domestic sales decreased by 5.08% to INR 35.55 Cr (from INR 37.45 Cr)...
No documents found
Pharma CDMO accounts for 62% of revenue (INR 736.9 Cr in FY25) but saw an 8% YoY decline in Q2 FY26 due to destocking; Specialty Chemicals grew 166% YoY in H1 FY26 on a low base; A...
No documents found
The Chronic segment (71.1% of revenue) grew at a 20.5% CAGR between MAT Jun-22 and MAT Jun-25, significantly outpacing the IPM Chronic growth of 10.1%. The Acute segment grew at a ...
Merchant export contract manufacturing is expected to grow by 50% YoY, contributing 10-15% of total revenue in FY26-27. Own-brand marketing, currently <1% of revenue, is targeted t...
The company operates in a single business segment (Intravenous Fluids). Total revenue grew by 2.98% YoY, reaching INR 173 Cr in FY 2024-25 compared to INR 168 Cr in FY 2023-24.
The company reported a turnover of INR 159.47 Cr in FY 2024-25, representing a 19.15% decrease from INR 197.24 Cr in FY 2023-24. Revenue is primarily driven by the anti-ulcerative ...
No documents found
Total income grew 30.7% YoY to INR 456.3 Cr in FY25, driven by generics, pet healthcare, nutraceuticals, and cosmeceuticals. 9MFY25 operating revenue grew 25.03% YoY to INR 288.86 ...
No documents found
The company operates in a single segment: Pharmaceutical Intermediates and APIs. Total revenue from operations for FY25 was INR 150.80 Cr, representing an 11.20% decrease from INR ...
Total revenue from operations grew 11.12% to INR 333.37 Cr in FY25. Segment-wise: Sale of APIs grew 4.67% to INR 204.99 Cr; Intermediates grew 16.33% to INR 98.89 Cr; and Sale of S...
Total revenue grew 39% YoY to INR 66.8 Cr in H1 FY26. Nutraceuticals (90% of revenue) grew 36.3% from INR 44.1 Cr to INR 60.1 Cr; Cosmetics (5% of revenue) grew 61.9% from INR 2.1 ...
The company operates exclusively in the pharmaceutical formulations segment, which generated total revenue of INR 15,841.25 Lacs in FY 2024-25, representing a growth of 8.03% YoY f...
Not disclosed in available documents; however, the company transitioned from cumulative losses of INR 32.61 Cr (FY 2006-07 to FY 2012-13) to cumulative profits of INR 12.39 Cr (FY ...
No documents found
Consolidated revenue from operations grew 20.52% YoY, reaching INR 370.20 Cr in FY25 compared to INR 307.17 Cr in FY24. Q1 FY26 revenue was reported at INR 111.9 Cr, indicating a s...
The company operates in a single Pharmaceutical Business segment. Revenue grew 2.2% YoY from INR 113.89 Cr in FY24 to INR 116.40 Cr in FY25, driven by direct sales and increased ca...
Operating income remained stagnant at approximately INR 75 Cr over the three fiscals through 2025. Specifically, revenue was INR 75.10 Cr in FY2025, representing a marginal decline...
The capsule business remains the primary revenue driver, growing 11.11% YoY to Rs. 45.80 Cr in Q2 FY26. The API segment is in a nascent stage, contributing only Rs. 1.22 Cr in reve...
Total income grew by 123.38% YoY, reaching INR 110.61 Cr in FY 2024-25 compared to INR 49.52 Cr in FY 2023-24. The company operates in a single segment: Pharmaceuticals.
The company operates in a single segment (Bulk Drugs). Total income grew by 2.39% YoY, reaching INR 110.25 Cr in FY25 compared to INR 107.68 Cr in FY24. Domestic sales grew 1.8% to...
No documents found
Revenue from operations for FY 2024-25 was INR 2.34 Cr (Rs. 234.09 lakhs). The company is transitioning into a science-based entity focusing on Contract Research, Development and M...
Operating revenue reached INR 4,120 million in Q2 FY26, representing a 39% YoY growth from INR 2,960 million. H1 FY26 revenue stood at INR 7,645 million, up 25% YoY from INR 6,127 ...
No documents found
Revenue from operations for H1 FY26 was INR 54.98 Cr, a decline of 4% YoY compared to INR 57.11 Cr in H1 FY25. Q2 FY26 revenue stood at INR 30.32 Cr, representing a 23% sequential ...
No documents found
Revenue from operations declined by 1.28% YoY, from INR 127.64 Cr in FY24 to INR 126.01 Cr in FY25. The API segment contributes over 80% of total revenue, while intermediates accou...
In H1 FY26, the Specialty business contributed 60% of revenue (growing significantly with the NSS acquisition), while the Pharma, Food, and Nutrition segment contributed 40%. In Q2...
The company operates in a single segment (APIs) and reported a 24% quarter-over-quarter increase in revenue for the quarter ending June 2025 compared to June 2024. However, a modes...
Total revenue from operations grew by 542% YoY, reaching INR 263.04 Lakhs in FY 2024-25 compared to INR 41 Lakhs in FY 2023-24. This growth was primarily driven by higher trading v...
Tablets and capsules (56% of revenue), Toothpaste/mouthwash/ointments (36%), Syrups (5%), Suspensions (3%). Revenue grew 53% YoY in H1FY26 to INR 47.90 Cr.
Overall revenue declined by 21.19% YoY, falling from INR 54.07 Cr in FY2016 to INR 42.61 Cr in FY2017, primarily due to a reduction in orders in hand. A longer-term decline is note...
Consolidated revenue declined by 24.15% YoY to INR 120.64 Cr in FY2025. Standalone revenue, primarily driven by domestic pharma and chemicals, fell 26.36% to INR 107.79 Cr. Histori...
No documents found